['type 2 diabetes mellitus']
['saxagliptin 5 mg', 'placebo 5 mg for saxagliptin', 'placebo 500 mg for metformin (with titration)', 'metformin 500 mg with titration']

        Inclusion Criteria:

        1. Subjects with type 2 diabetes mellitus; 2. HbA1c ≥8% but ≤12%; 3.Fasting C-peptide ≥1.0
        ng/ml; 4. Subject will be drug naïve; 5. Body mass index ≤40 kg/m2.

        Exclusion Criteria:

        1. Symptoms of poorly controlled diabetes; 2. Chronic or repeated intermittent
        corticosteroid treatment ; 3. Calculated creatinine clearance <60 ml/min or serum
        creatinine >132.6 μmol/L (>1.5 mg/dL) for men, >123.8 μmol/L (>1.4 mg/dL) for women; 4.
        Creatine Kinase ≥3x ULN; 5.Abnormal TSH value at screening will be further evaluated by
        free T4, subjects with an abnormal free T4 will be excluded; 6. History of administration
        of any antihyperglycaemic therapy for a total of 28 days or for more than three consecutive
        days or a total of seven non-consecutive days during the eight weeks prior to screening; 7.
        Current treatment with a strong CYP3A4/5 inhibitor; 8. Prior treatment with saxagliptin or
        any DPP-4 inhibitor; 9. Significant or history of cardiovascular disease, renal disease,
        psychiatric disorders, Immunocompromised individuals, hemoglobinopathies, liver disease,
        Pancreatitis.
      